Table 6 Comparison of clinical data for ANA-positive RR-positive, ANA-positive RR-negative, and ANA-negative patients
From: High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection
Clinical characteristic | RR-positive N (%) | RR-negative N (%) | ANA-negative N (%) | p-value |
|---|---|---|---|---|
Systemic arterial hypertension | 6 (54.55%) | 2 (28.57%) | 24 (35.82%) | 0.4629 |
Diabetes mellitus 2 | 2 (18.18%) | 0 | 13 (19.4%) | 0.2778 |
Hepatomegaly | 0 | 0 | 11 (16.4%) | 0.0864 |
Hepatic steatosis | 2 (18.18%) | 3 (60%) | 11 (17.1%) | 0.1243 |
Cirrhosis | 4 (36.36%) | 2 (28.57%) | 9 (12.7%) | 0.1716 |
Inflammatory activityG | ||||
A0 | 0 | 1 (33.3%) | 4 (4.59%) | |
A1 | 6 (66.7%) | 1 (33.3%) | 27 (33.7%) | 0.5442 |
A2 | 3 (33.3%) | 1 (33.3%) | 18 (26.5%) | |
A3 | 0 | 0 | 4 (5.9%) | |
Degree of fibrosisG | ||||
F0 | 0 | 0 | 4 (7.55%) | |
F1 | 0 | 2 (66.7%) | 20 (37.73%) | |
F2 | 3 (33.3%) | 0 | 16 (30.18%) | 0.0165 |
F3 | 3 (33.3%) | 1 (33.3%) | 12 (22.64%) | |
F4 | 3 (33.3%) | 0 | 1 (1.89%) | |